LON:GNS - Genus Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 2,666 -24.00 (-0.89 %) (As of 05/23/2019 01:18 PM ET)Previous CloseGBX 2,690Today's RangeGBX 2,638 - GBX 2,71052-Week RangeGBX 2,090 - GBX 2,998Volume71,618 shsAverage Volume78,154 shsMarket Capitalization£1.72 billionP/E RatioN/ADividend Yield1.11%BetaN/A ProfileAnalyst RatingsChartDividendInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos, which are delivered through artificial insemination to breed dairy and beef cattle with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers; and agricultural and agri-food consultancy services. Genus plc was incorporated in 1994 and is headquartered in Basingstoke, the United Kingdom. Receive GNS News and Ratings via Email Sign-up to receive the latest news and ratings for GNS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:GNS Previous Symbol CUSIPN/A CIKN/A Webhttp://www.genusplc.com/ Phone+44-1256-347100Debt Debt-to-Equity Ratio22.58 Current Ratio2.08 Quick Ratio1.32Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio0.33 P/E GrowthN/A Sales & Book Value Annual Sales£470.50 million Price / Sales3.65 Cash FlowGBX 37.53 per share Price / Cash Flow71.03 Book ValueGBX 789.10 per share Price / Book3.38Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees2,900 Outstanding Shares64,467,200Market Cap£1.72 billion Next Earnings DateN/A OptionableNot Optionable Genus (LON:GNS) Frequently Asked Questions What is Genus' stock symbol? Genus trades on the London Stock Exchange (LON) under the ticker symbol "GNS." How often does Genus pay dividends? What is the dividend yield for Genus? Genus declared a dividend on Thursday, February 28th. Stockholders of record on Thursday, March 7th will be paid a dividend of GBX 8.90 per share on Thursday, April 4th. This represents a dividend yield of 0.41%. The ex-dividend date of this dividend is Thursday, March 7th. The official announcement can be viewed at this link. View Genus' Dividend History. What price target have analysts set for GNS? 4 Wall Street analysts have issued 12 month price objectives for Genus' shares. Their forecasts range from GBX 2,500 to GBX 3,200. On average, they anticipate Genus' stock price to reach GBX 2,757.50 in the next year. This suggests a possible upside of 3.4% from the stock's current price. View Analyst Price Targets for Genus. What is the consensus analysts' recommendation for Genus? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genus. Has Genus been receiving favorable news coverage? News stories about GNS stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genus earned a media sentiment score of 1.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Genus' key competitors? Some companies that are related to Genus include MorphoSys (MOR), BTG (BTG), MorphoSys (MOR), Abcam (ABC), Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), ProMetic Life Sciences (PLI), Mesoblast (MSB), Polynovo (PNV), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Starpharma (SPL), Biotest (BIO), Oxford BioMedica (OXB) and Neptune Wellness Solutions (NEPT). What other stocks do shareholders of Genus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genus investors own include Clinigen Group (CLIN), Glencore (GLEN), Tesco (TSCO), AstraZeneca (AZN), British American Tobacco Plc Ads (BATS), Dairy Crest Group (DCG), Debenhams (DEB), Diageo (DGE), Experian (EXPN) and Ferguson (FERG). Who are Genus' key executives? Genus' management team includes the folowing people: Mr. Karim Bitar, CEO & Exec. Director (Age 54)Mr. Stephen Wilson, Group Fin. Director & Exec. Director (Age 59)Dr. Jonathan Lightner, Chief of R&D and Scientific OfficerMr. Dan Hartley, Group Gen. Counsel & Company Sec.Ms. Angelle R. Rosata, Group HR Director How do I buy shares of Genus? Shares of GNS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Genus' stock price today? One share of GNS stock can currently be purchased for approximately GBX 2,666. How big of a company is Genus? Genus has a market capitalization of £1.72 billion and generates £470.50 million in revenue each year. Genus employs 2,900 workers across the globe. What is Genus' official website? The official website for Genus is http://www.genusplc.com/. How can I contact Genus? Genus' mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The company can be reached via phone at +44-1256-347100. MarketBeat Community Rating for Genus (LON GNS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 291 (Vote Outperform)Underperform Votes: 260 (Vote Underperform)Total Votes: 551MarketBeat's community ratings are surveys of what our community members think about Genus and other stocks. Vote "Outperform" if you believe GNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: How do CD ladders protect against rising interest rates? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.